ME03678B - Unapređena alfa-v beta-8 antitela - Google Patents

Unapređena alfa-v beta-8 antitela

Info

Publication number
ME03678B
ME03678B MEP-2020-57A MEP202057A ME03678B ME 03678 B ME03678 B ME 03678B ME P202057 A MEP202057 A ME P202057A ME 03678 B ME03678 B ME 03678B
Authority
ME
Montenegro
Prior art keywords
antibodies
beta
enhanced alpha
alpha
enhanced
Prior art date
Application number
MEP-2020-57A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stephen Nishimura
Jianlong Lou
Anthony Cormier
Jody Lynn Baron
James D Marks
Lynne Murray
Ping Tsui
Yanli Wu
Original Assignee
Univ California
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Medimmune Ltd filed Critical Univ California
Publication of ME03678B publication Critical patent/ME03678B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-2020-57A 2014-06-17 2015-06-17 Unapređena alfa-v beta-8 antitela ME03678B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013114P 2014-06-17 2014-06-17
EP15809699.0A EP3157561B1 (en) 2014-06-17 2015-06-17 Improved alpha-v beta-8 antibodies
PCT/US2015/036284 WO2015195835A2 (en) 2014-06-17 2015-06-17 Improved alpha-v beta-8 antibodies

Publications (1)

Publication Number Publication Date
ME03678B true ME03678B (me) 2020-10-20

Family

ID=54936235

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-57A ME03678B (me) 2014-06-17 2015-06-17 Unapređena alfa-v beta-8 antitela

Country Status (17)

Country Link
US (2) US20170129955A1 (me)
EP (1) EP3157561B1 (me)
JP (2) JP2017522289A (me)
CN (1) CN107405396A (me)
CY (1) CY1123219T1 (me)
DK (1) DK3157561T3 (me)
ES (1) ES2779412T3 (me)
HR (1) HRP20200420T1 (me)
HU (1) HUE048663T2 (me)
LT (1) LT3157561T (me)
ME (1) ME03678B (me)
PL (1) PL3157561T3 (me)
PT (1) PT3157561T (me)
RS (1) RS60061B1 (me)
SI (1) SI3157561T1 (me)
SM (1) SMT202000146T1 (me)
WO (1) WO2015195835A2 (me)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019336197A1 (en) * 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用
WO2025256659A1 (zh) * 2024-06-14 2025-12-18 迈威(上海)生物科技股份有限公司 一种抗人整合素αvβ8的抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7786270B2 (en) * 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
CN105315370A (zh) * 2010-02-18 2016-02-10 加利福尼亚大学董事会 整合素αVβ8中和抗体
JP6093360B2 (ja) * 2011-08-17 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンα−ｖβ−８と結合する抗体

Also Published As

Publication number Publication date
ES2779412T3 (es) 2020-08-17
HRP20200420T1 (hr) 2020-06-26
US20170129955A1 (en) 2017-05-11
CN107405396A (zh) 2017-11-28
LT3157561T (lt) 2020-07-10
PL3157561T3 (pl) 2020-06-29
SI3157561T1 (sl) 2020-08-31
SMT202000146T1 (it) 2020-05-08
CY1123219T1 (el) 2021-10-29
EP3157561B1 (en) 2019-12-18
EP3157561A4 (en) 2018-02-28
DK3157561T3 (da) 2020-03-23
JP2017522289A (ja) 2017-08-10
RS60061B1 (sr) 2020-04-30
WO2015195835A2 (en) 2015-12-23
PT3157561T (pt) 2020-03-25
WO2015195835A3 (en) 2016-03-10
US20200277381A1 (en) 2020-09-03
JP2020183425A (ja) 2020-11-12
EP3157561A2 (en) 2017-04-26
HUE048663T2 (hu) 2020-07-28

Similar Documents

Publication Publication Date Title
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
IL251963A0 (en) Anti-pd-1 antibodies
EP3334757A4 (en) ANTI-Tigit ANTIBODY
MA47472A (fr) Anticorps
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
PL3556777T3 (pl) Konstrukty przeciwciał wieloswoistych
DK3344654T3 (da) Anti-lag-3-antistoffer
MA53297A (fr) Anticorps anti-icos
DK3119885T3 (da) Antistof-fynomer-konjugater
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3174483T3 (da) Hyporørkonstruktion
EP3319983C0 (en) TAU LINKING ANTIBODIES
IL291164A (en) Anti-nme antibody
DK3148591T3 (da) Nanopartikel-lægemiddelkonjugater
MA51554A (fr) Anticorps il-6 améliorés
EP3349794A4 (en) Anti-cd115 antibodies
EP3381941A4 (en) ANTI-EPHA4 ANTIBODY
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
EP3336185A4 (en) ANTIBODY
EP3212232A4 (en) TETRAVALENT TLR9 BISPECIFIC ANTIBODIES
EP3336184A4 (en) ANTIBODY
LT3178931T (lt) Anti-orai1 antikūnas